期刊文献+

肝癌干细胞靶向治疗的研究进展 被引量:1

Research progress in targeted therapy for liver cancer stem cells
下载PDF
导出
摘要 肝癌是一种恶性肿瘤,目前的手术、放化疗均不能取得满意疗效,复发、转移一直是肝癌治疗的难题。根据近些年研究的肝癌干细胞学说,肝癌的发生、发展、复发、转移、预后都与肝癌干细胞有关。如果靶向作用于肝癌的干细胞,使其数目减少或者被消灭掉,就会使肿瘤切除术后的复发、转移性及耐药性降低或被清除。对肝癌干细胞的靶向治疗进展情况作一综述,认为肝癌干细胞的靶向治疗方法虽然有很多种,但是靶向性不强仍然是亟需解决的关键问题,是否可以通过双靶向或者多靶向联合解决靶向性的问题还需要进一步的实验研究证实。 Liver cancer is a malignant tumor. The current operation or chemoradiotherapy cannot achieve a satisfactory effect, and relapse and metastasis are always big problems in the treatment of liver cancer. According to the recent theory of liver cancer stem cells, the genesis, development, relapse, metastasis, and prognosis of liver cancer are all related to liver cancer stem cells. If the liver cancer stem cells are treated by targeted therapy, which would reduce the number of or destroy the stem cells, the relapse, metastasis, and drug resistance after tumor resection may be reduced or eliminated. The progress in targeted therapy for liver cancer stem cells is reviewed here. Although there are many types of targeted therapies for liver cancer stem cells, it is still a key problem that the targeting is not strong enough, which needs to be solved urgently. Whether the dual - or multi -targeting would solve this problem still needs to be confirmed by further experimental studies.
出处 《临床肝胆病杂志》 CAS 2015年第11期1933-1936,共4页 Journal of Clinical Hepatology
关键词 肝肿瘤 肿瘤干细胞 治疗 综述 liver neoplasms neoplastic stem cells therapy review
  • 相关文献

参考文献7

二级参考文献128

  • 1Yan Li Zhao-You Tang Sheng-Long Ye Yin-Kun Liu Jie Chen Qiong Xue Jun Chen Dong-Mei Gao Wei-Hua Bao Liver Cancer Institute and Zhongshan Hospital of Fudan University (Former Liver Cancer Institute of Shanghai Medical University),Shanghai 200032,China.Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97[J].World Journal of Gastroenterology,2001,7(5):630-636. 被引量:112
  • 2Hong-mei P Gui-an C.Serum-free medium cultivation to improve efficacy in establishment of human embryonic stem cell lines[J].中国生物学文摘,2006,20(7):21-21. 被引量:34
  • 3鞠晓芳,安铁洙,滕春波.干细胞巢研究进展[J].生理科学进展,2007,38(3):213-218. 被引量:4
  • 4Huang S, He J, Zhang X, Bian Y, Yang L, Xie G, Zhang K et al. Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 2006, 27:1334-1340.
  • 5Sicklick JK, Li YX, Jayaraman A, Kannangai R, Qi Y, Vivekanandan P, Ludlow JW et al. Dysregulation of the hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 2006, 27:748-757.
  • 6Lin SL, Chang SJ, Ying SY. Transcriptional control of SHh/PTC1 signaling in embryonic development. Gene 2006, 367:56-65.
  • 7Kim Y, Yoon JW, Xiao X, Dean NM, Monia BP, Marcusson EG. Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res 2007, 67:3583-3593.
  • 8Omenetti A, Diehl AM. The adventures of sonic hedgehog in development and repair II. Sonic hedgehog and liver development, inflammation, and cancer. Am J Physiol Gastrointest Liver Physiol 2008, 294:595-598.
  • 9Akiyoshi T, Nakamura M, Koga K, Nakashima H, Yao T, Tsuneyoshi M, Tanaka Met al. Glil, downregulated in colorectal cancers, inhibits proliferation of colon cancer cells involving Wnt signaling activation. Gut 2006, 55:991-999.
  • 10Lewis MT, Visbal AP. The hedgehog signaling network, mammary stem cells, and breast cancer: connections and controversies. Ernst Schering Found Symp Proc 2006,5:181-217.

共引文献29

同被引文献17

  • 1Palandri F,ZoliM ,Polverelli N, et al. MYH9-related thrombocy- topenia and intracranial bleedings:a complex clinical/surgical manage- ment and review of the literature[J]. Br J Haematol, 2015,170 (5) : 729- 731.
  • 2Okano S, Takase M, Iseki K,et al. Genotype-phenotype correlation of the p.Rl165C mutation in the MYH9 disorder:report of a Japanese pedigree[J]. J PediatrHematolOncol, 2015,37(6) : e352-355.
  • 3Girolami A,Sambado L, Bonamigo E,et al. Occurrence of throm- bosis in congenital thrombocytopenic disorders:a critical annotation of the literature[J]. Blood Coagul Fibrinolysis, 2013,24( 1 ) : 18-22.
  • 4Arora S,Saha S,Roy S,et al. Role of nonmuscle myosin Ⅱ in mi- gration of Wharton's Jelly-derived mesenchymal stem cells[J]. Stem Cells Dev, 2015,24(17) : 2065-2077.
  • 5Katono K,Sato Y,Jiang SX,et al. Prognostic significance of MYH9 expression in resected non-small cell lung cancer[J]. PLoS One,2015, 10(3) :e0121460.
  • 6Verver EJ,Topsakal V,Kunst HP,et al. Nonmuscle myosin heavy chain ⅡA mutation predicts severity and progression of sensorineural hearing loss in patients with MYH9-related disease[J]. Ear Hear, 2016, 37(1 ) : 112-120.
  • 7Kovacs M,Toth J,Nyitray L,et al. Two-headed binding of the unphosphory|atednonmuscle heavy meromyosin. ADP complex to actin [J]. Biochemistry, 2004,43 (14) : 4219-4226.
  • 8Badirou I, Pan J, Souquere S, et al. Distinct localizations and roles of non-muscle myosin Ⅱ during proplatelet formation and platelet re- lease[J]. J ThrombHaemost, 2015,13<5) : 851-859.
  • 9Liu D,Zhang L,Shen Z,et al. Clinicopathological significance of NMIIA overexpression in human gastric cancer[J]. Int J MolSci,2012, 13 (11) : 15291-15304.
  • 10Sun H,Wang X,Zhang Y,et al. Biglycan enhances the ability of migration and invasion in endometrial cancer[J]. Arch GynecolObstet, 2016,293 ( 2 ) : 429-438.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部